Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

Analyst Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report) and increased the price target to $47.00 from $46.00. Don't Miss our Black Friday ...

The approval was based on positive results observed in the ATTRibute-CM Phase 3 study, where Attruby demonstrated a ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

U.S.-based travel companies, from Marriott International to Booking Holdings are trimming their budgets and workforce ahead ...

Invesco Health Care Fund underperformed its benchmark. Despite earlier signs of improving trends, our health care outlook is ...

Deal Could End Israel-Hezbollah Conflict That Has Lasted Over a Year Lebanon’s caretaker cabinet is expected to meet to formally approve the deal, in which it would play an essential role. Maps ...

Stewart-Haas' sad demise belies its legacy of unlikely success (October 31, 2024, 7:00 PM ET) ...

Lockheed Martin has felt financial strain as early funding for the upcoming F-35 jets dried up, but kept working on them to avoid supply chain disruptions.

#ex-Czech PM (Yonhap Interview) Ex-Czech PM optimistic on nuclear power plant partnership with S. Korea By Kim Seung-yeon SEOUL, Nov. 27 (Yonhap) -- A former prime minister of the Czech Republic ...

Netflix announced in April 2024 that it had officially ordered and put into production a new action thriller called Ad Vitam, which translates to To Life in English. The movie has since completed ...